News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
ViaCyte Awarded New CIRM Grant To Develop PEC-Direct For High-Risk Type 1 Diabetes 7/22/2016
Resverlogix (RVX.TO) Announces Dosing Of First Two Patients In Expanded Renal And Orphan Programs 7/22/2016
FDA Calls Pfizer (PFE), Spark Therapeutics (ONCE)'s Hemophilia B Drug a Breakthrough 7/22/2016
BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Precisely To The Skin 7/21/2016
TRANSGENE (ENX:TNG) To Continue Phase I/Ib Study With TG1050 In Chronic Hepatitis B Patients On The Recommendation Of The Trial’s Safety Review Committee 7/21/2016
AveXis' Spine Therapy Wins Breakthrough Tag From the FDA 7/20/2016
Pulmatrix And Mylan (MYL) Report Positive Pharmacokinetic Bioavailability Data In Pilot Study Of PUR0200 In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/19/2016
ProQR Therapeutics B.V. (PRQR) Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis 7/19/2016
Cytori Therapeutics (CYTX) Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration 7/19/2016
Navidea (NAVB) Receives IRB Approval For Its Lymphoseek Rheumatoid Arthritis Clinical Trial Protocol 7/19/2016
Updated Data For Epacadostat, Incyte (INCY)’s Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016 7/19/2016
Symcel Release: Initial €50,000 Phase 1 Grant Will Fund Full Feasibility Study 7/18/2016
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research 7/18/2016
ZIOPHARM Abandons $50 Million Stock Offering After Clinical Trial Deaths 7/18/2016
MabVax Therapeutics Initiates Patient Enrollment In A Phase I Trial For A New Diagnostic Imaging Product For Pancreatic Cancer 7/18/2016
Champions Oncology, Inc. (CSBR) Successfully Delivers First AML Study 7/18/2016
Bexion Pharmaceuticals Receives FDA Clearance For The First Clinical Trial Using BXQ-350 To Dose Patients With Cancer 7/18/2016
With Little Fanfare, Biogen (BIIB) Sneaks Lupus Drug Into a Phase I Trial 7/15/2016
Armagen Presents Data From First Cohort Of Phase 1/2a Of AGT-182 For Treatment Of Hunter Syndrome 7/15/2016
ProtoKinetix Inc. (PKTX.OB)’ 2nd Quarter Scientific Update 7/14/2016
Alexion (ALXN) Presents New SBC-103 (rhNAGLU Enzyme) Phase I/II Data On Brain MRI And Neurocognitive Assessments In Patients With Mucopolysaccharidosis IIIB (MPS IIIB) 7/14/2016
Celyad Successfully Completes Safety Follow-Up Of The First Patient At The Fourth Dose Level In The NKR-2 Phase I Trial 7/14/2016
Oncternal Therapeutics' TK216 Receives Orphan Drug Designation For The Treatment Of Ewing Sarcoma, A Rare Pediatric Cancer 7/13/2016
Aptinyx Initiates Dosing In Phase 1 Clinical Study Of Lead NMDA-Receptor Modulator, NYX-2925 7/13/2016
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection 7/13/2016
TARIS Biomedical Initiates Phase Ib Clinical Trial Of TAR-200 (Gemris™) In Patients With Muscle-Invasive Bladder Cancer 7/13/2016
Oncodesign SA Announces The Launch Of Its First Clinical Study On A Radiotracer In Patients With Non-Small Cell Lung Cancer 7/13/2016
Mologen (MOLGF.PK): First Patient Recruited In Combination Study With Lefitolimod And Yervoy 7/13/2016
VAXIMM Initiates Phase 1 Translational Study In Glioblastoma With Oral T-Cell Immunotherapy, VXM01 7/12/2016
3 Nauseating Clinical Trial Flops of 2016 So Far 7/12/2016
Asterias Biotherapeutics Completes Enrollment And Dosing For The First Efficacy Cohort Of The AST-OPC1 Scistar Phase 1/2a Clinical Trial In Complete Cervical Spinal Cord Injury 7/12/2016
Celldex (CLDX) Initiates Phase I/II Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma 7/12/2016
Akari Therapeutics Receives Positive Opinion For Orphan Drug Designation For Coversin In The European Union For Treatment Of Paroxysmal Nocturnal Hemoglobinuria 7/12/2016
uniQure (QURE) Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress 7/11/2016
Zavante Therapeutics Enrolls First Patient In The ZEUS Study For ZTI-01 For The Treatment Of Complicated Urinary Tract Infections 7/11/2016
Acceleron Pharma Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases 7/8/2016
China's BeiGene (BGNE) Starts Combination Trial For Two Novel Cancer Drugs 7/7/2016
Seres Therapeutics Announces Initiation Of A Phase 1b Clinical Trial Of SER-262 For Primary Clostridium difficile Infection 7/7/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine 7/7/2016
Nanobiotix Reports Successful Results From Phase I/II Trial Of NBTXR3 In Head & Neck Cancer 7/7/2016
Minoryx Therapeutics Initiates Phase 1 Clinical Trial Of MIN-102 7/6/2016
AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial 7/6/2016
Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
Heptares Anounces Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
miRagen To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 7/6/2016
Lysogene Begins Multi-National Observational Study As It Prepares To Initiate Pivotal Clinical Trial For The Treatment Of Sanfilippo Type A 7/6/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far! 7/6/2016
Regulus (RGLS) To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference 7/5/2016
Leap Therapeutics Presents Positive Data From Clinical Study Of DKN-01 In Combination With Paclitaxel In Esophageal Cancer 6/30/2016
First-In-Human Study Of Immbio's Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine To Be Safe And Immunogenic 6/30/2016
Cytune Pharma SAS Secures EUR 6M In Financing To Advance Lead Immuno-Oncology Program To Phase I 6/30/2016
First-Ever CRISPR Trial Points to Looming Problems 6/30/2016
PsiOxus Gets Upfront $10 Million, Ties Immuno-Oncology Clinical Pact With Bristol-Myers Squibb (BMY) 6/30/2016
Janssen Pharmaceutical Companies Release: Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation By FDA For The Development Of A Treatment For Chronic Graft-Versus-Host Disease (cGVHD) 6/29/2016
Cascadian Therapeutics (ONTY) Receives ONT-380 Fast Track Designation From FDA For The Treatment Of Advanced HER2+ Metastatic Breast Cancer 6/29/2016
Actinium Pharmaceuticals, Inc. (ATNM.OB) Initiates Pivotal Phase 3 SIERRA Trial 6/29/2016
Acceleron Pharma Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease 6/29/2016
Symphogen Advances Sym015 Into Clinical Development Using Selexis SA SGEs (Selexis Genetic Elements) 6/29/2016
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease 6/29/2016
Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 At Eilat Conference On New Antiepileptic Drugs 6/28/2016
Neuromax Announces Start Phase 1 Clinical Trial Of AQU-005 For The Treatment Of Neuropathic Pain 6/28/2016
Vaxart Initiates Clinical Development Of First Oral RSV Vaccine 6/28/2016
MRI' Clearpoint Neuro Navigation Technology Highlighted In Voyager Therapeutics (VYGR) Interim Parkinson’s Disease Gene Therapy Study Results 6/24/2016
City of Hope, Novonco Announce First-In-Human Clinical Trial For COH29 6/24/2016
SanBio, Inc. Presents Interim Results Of Chronic Stroke Phase I/IIa Clinical Trial At International Society Of Stem Cell Research Annual Meeting 6/24/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Apellis Pharma Announces Positive Results From Phase 1 Clinical Trials Of APL-2, A C3 Complement Inhibitor 6/23/2016
Cellectar Biosciences  (NVLT) Announces Results Of NCI-Sponsored Study Of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer 6/23/2016
Retrophin (RTRX) Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson’s Disease And Movement Disorders 6/23/2016
CytoSorbents Awarded $150,000 Phase I STTR Contract For Universal Plasma Development 6/22/2016
ViaCyte To Present At ISSCR 2016 Annual Meeting 6/22/2016
Voyager Therapeutics (VYGR) Announces Interim Phase 1b Surgical Results For VY-AADC01 In Advanced Parkinson’s Disease 6/22/2016
Agenus (AGEN) Announces Commencement Of Phase I/II Clinical Trial Of Anti-GITR Checkpoint Antibody INCAGN1876 In Patients With Solid Tumors 6/22/2016
Inovio Pharma (INO): The Surprising Leader in the Zika Vaccine Race 6/21/2016
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016
Global Blood Therapeutics (GBT) Announces Pricing Of Public Offering Of Common Stock 6/21/2016
ProQR Therapeutics B.V. (PRQR) To Release Topline Data From Proof Of Concept Study Of QR-010 In Cystic Fibrosis Patients At NACFC 6/21/2016
Seres Therapeutics Presents New Data At American Society for Microbiology Microbe 2016, Including Characterization Of SER-262, The Rationally-Designed, Fermented Microbiome Therapeutic Candidate For Primary Clostridium Difficile Infection 6/21/2016
Cellectis (ALCLS) Announces First Patient Treated In Phase 1 Trial Of UCART19 In Pediatric Acute B Lymphoblastic Leukemia (B-ALL) 6/21/2016
Asterias Biotherapeutics Announces Oral Presentation And Participation In Panel Discussion At The ISSCR 14th Annual Meeting 6/21/2016
Fate Therapeutics (FATE) Announces FDA Fast Track Designation For Protmune 6/20/2016
Poxel SAS Announces Positive Results From the First Stage Of The Ongoing PXL770 Phase 1 Trial 6/20/2016
Oncternal Therapeutics Receives Fast Track Designation For TK216 In Relapsed Or Refractory Ewing Sarcoma 6/20/2016
Gilead (GILD) Presents Preliminary Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV 6/20/2016
Unum Announces Active Investigational New Drug (IND) Application For ACTR087 In Patients With Relapsed/Refractory B-Cell Lymphoma 6/20/2016
Enanta Pharmaceuticals, Inc. Initiates Proof-Of-Concept Study With Pan-Genotypic Cyclophilin Inhibitor EDP-494 In Patients With Genotype 1 Or Genotype 3 Chronic Hepatitis C Virus 6/20/2016
Juniper Pharma (JNP) Announces Phase 1 Studies Of COL-1077 Lidocaine Vaginal Gel Published In Peer Reviewed Scientific Journal 6/17/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues 6/17/2016
BioMarin (BMRN) Stock Wobbles After Hemophilia A Trial Suspended 6/17/2016
Zenith Announces Dosing Of First Patient In Phase 1 Clinical Trial And Corporate Update Webcast Details 6/16/2016
Pfizer (PFE) Head of R&D Talks Strategy on How Pharma Chooses Compounds to Bet A Billion Dollars On 6/16/2016
Capricor Therapeutics, Inc. Reports Positive 12-Month Data From The DYNAMIC Clinical Trial 6/16/2016
Senhwa Announces Enrollment Of First Patient In Phase I/II CX-5461 Trial In Triple Negative Breast Cancer 6/15/2016
Cascadian Therapeutics (ONTY) Reports Topline ONT-380 "Triplet" Data and Outlines Key Development Strategies 6/14/2016
MabVax Therapeutics Launches Second Investigational Site With Sarah Cannon Research Institute In Ongoing Phase I Clinical Trial To Evaluate New Treatment For Pancreatic Cancer 6/14/2016
uniQure (QURE) Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity 6/13/2016
Fibrocell (FCSC) Announces Initiation Of Patient Recruitment In Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 6/13/2016
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Receives FDA Fast Track Designation For Treatment Of Acute Myeloid Leukemia 6/13/2016
True North Therapeutics ’s Lead Product Candidate, TNT009, Demonstrates High Response Rates And Rapid Onset Of Action In Interim Clinical Data In Patients With Cold Agglutinin Disease (CAD) 6/13/2016
Eleven Bio (EBIO) Announces Investigational New Drug Application Submission To Initiate Clinical Trials Of EBI-031 For Ocular Diseases 6/13/2016
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD 6/13/2016
True North Therapeutics To Present Clinical Data In Patients With Cold Agglutinin Disease (CAD) For Lead Product Candidate TNT009 6/13/2016
Concert Pharmaceuticals, Inc. (CNCE) Presents CTP-656 Phase I Results At European Cystic Fibrosis Conference 6/13/2016
Prothena (PRTA) Presents First Clinical Data for PRX003 for the Treatment of Inflammatory Diseases 6/10/2016
Achillion (ACHN) Presents Interim Phase I Results For ACH-4471, A Novel Orally-Administered Factor D Inhibitor, At The 21st Congress Of The European Hematology Association 6/10/2016
Ra Pharma Presents Clinical Data On Complement C5 Inhibitor RA101495 At The 21st Congress Of The European Hematology Association 6/10/2016
Alexion (ALXN) Release: Late-Breaking Data Presented At European Hematology Association: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase I/II Study Exhibit Rapid And Sustained Reductions In LDH 6/10/2016
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Yields High Remission Rates And Favorable Tolerability In Phase I Portion Of Phase I/II Clinical Trial For AML 6/10/2016
Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin® Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity 6/10/2016
Concert Pharmaceuticals, Inc. (CNCE) Presents CTP-656 Phase I Results At European Cystic Fibrosis Conference 6/10/2016
Global Blood Therapeutics (GBT) Stock Surges on Promising Sickle Cell Drug Results 6/10/2016
Cerulean Pharma Inc. (CERU) Announces Manuscript Published in Annals of Oncology 6/9/2016
Alnylam (ALNY) Initiates Phase I Clinical Trial For ALN-Ttrsc02, An Investigational Rnai Therapeutic For The Treatment Of TTR-Mediated Amyloidosis 6/9/2016
New Data Presented At The Annual European Congress Of Rheumatology (EULAR 2016) Demonstrate Safety And Efficacy Of Biogen (BIIB)’s Anti-TNF Biosimilars Portfolio 6/9/2016
Acorda (ACOR) Presents Phase I Data On CVT-427 For Acute Treatment Of Migraine At 58th Annual Scientific Meeting Of The American Headache Society 6/9/2016
Theravance Biopharma (TBPH) Reports Positive Results From Phase 1 Clinical Trial Of TD-1473, A GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 6/9/2016
Arrowhead Pharma (ARWR) Initiates Phase I/II Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521 6/9/2016
Galderma Laboratories Trifarotene Development Program Meets Key Milestone For Lamellar Ichthyosis Orphan Disease 6/9/2016
Paradigm Provides Clinical Trial Update 6/9/2016
ASCO2016: What's Next For Cancer-Killing T-Cells After Strong ASCO Showings 6/8/2016
Cidara Therapeutics (CDTX) To Present Data On Lead Antifungal Product Candidate CD101 At Upcoming ASM Microbe 2016 6/8/2016
NGM Initiates Phase 1 Clinical Trial Of NGM313, A Proprietary Antibody With The Potential To Treat Type 2 Diabetes, Obesity And NASH 6/8/2016
ASCO2016: Boston Biomedical Featured Seven Clinical Posters On Cancer Stem Cell Pathway Inhibitors Napabucasin And Amcasertib In Multiple Cancer Types At ASCO 2016 6/8/2016
ASCO2016: Immune Design Corporation (IMDZ) Releases New PFS, OS And TME Data From Trials Of Three Immuno-Oncology Product Candidates 6/8/2016
Curis (CRIS) Announces Oral Presentation Of Clinical Data Update From The Phase I Study Of CUDC-907 At The 21st Congress Of The European Hematology Association 6/8/2016
Bristol-Myers Squibb (BMY) Announces New Rheumatoid Arthritis Research And Real-World Data At The Annual European Congress Of Rheumatology (EULAR 2016) 6/8/2016
Kite Pharma (KITE) To Highlight Key Data From CAR T-Cell Therapy Pipeline In Oral Presentations At The 2016 European Hematology Association Annual Congress 6/8/2016
GenSight Biologics Announces Additional Promising Results Of Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/8/2016
SAGE Therapeutics (SAGE) Reports Positive Top-Line Results From Phase I Clinical Program Of SAGE-217 6/8/2016
Immunocore’s Immtav Shown To Redirect The Immune System To Kill HIV-Infected Cells From Patients Treated With Antiretroviral Therapy 6/8/2016
MabVax Therapeutics Expands Patient Enrollment In Phase I Trial For Treatment Of Pancreatic Cancer To Memorial Sloan-Kettering Cancer Center 6/7/2016
TapImmune (TPIV) Announces Finalization Of License Agreement With Mayo Clinic To Commercialize A HER2neu Vaccine 6/7/2016
ASCO2016: BerGenBio AS Reports First-In-Patient Phase 1 Data For BGB324 In Patients With Myeloid Malignancies At The 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 6/7/2016
Living Cell Tech's NTCELL Demonstrates Continued Reversal Of Parkinson's Disease 6/7/2016
ASCO2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data As An Immuno-Oncology Monotherapy And In Combination With An Anti-PD-1 Checkpoint Inhibitor In Advanced Solid Tumors, Including Immune-Resistant Cancers 6/6/2016
Agios (AGIO) Reports Initial Data From Phase I Study Of AG-519 In Healthy Volunteers 6/6/2016
ASCO2016: Kolltan Pharmaceuticals Inc. Presents Clinical Data For KTN3379 In An Oral Presentation At The 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 6/6/2016
ASCO2016: Galera Announces Presentation At ASCO Of Positive Results From Study Of GC4419 For The Reduction Of Severe Oral Mucositis 6/6/2016
ASCO2016: Principia Biopharma Announces Presentation Of Initial Clinical Data On PRN1371 At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016
ASCO2016: Pfizer (PFE) Presents Promising Data From Next Generation ALK/ROS1 Inhibitor In Advanced Non-Small Cell Lung Cancer 6/6/2016
ASCO2016: Seattle Genetics (SGEN) And Astellas (ALPMY) Present ASG-15ME And Enfortumab Vedotin Phase I Clinical Data In Metastatic Urothelial Cancer At ASCO Annual Meeting 6/6/2016
Results Of Phase 1a/1b Study Of AbbVie (ABBV)'s Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate Of 39 Percent In Pretreated Patients With Biomarker-Defined Small Cell Lung Cancer (SCLC) 6/6/2016
ASCO2016: Kite Pharma (KITE) Announces The First Meta-Analysis Of Outcomes In Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1) 6/6/2016
New Study Led By John Theurer Cancer Center Researcher Demonstrates Potential Therapeutic Benefit Of TPI 287 With Bevacizumab In Treatment Of Aggressive Brain Cancer 6/6/2016
ASCO2016: Merrimack (MACK) Release: Final Analysis Of First-In-Human Phase 1 Study Of MM-151 Shows Positive Clinical Activity In Multiple Solid Tumor Types, Including Colorectal Cancer 6/6/2016
ASCO2016: Early-Phase Immuno-Oncology Studies Of Eli Lilly (LLY)'s ALIMTA (Pemetrexed) And CYRAMZA (Ramucirumab) With Merck & Co. (MRK)'s KEYTRUDA (Pembrolizumab) Show Encouraging Results In Non-Small Cell Lung Cancer 6/6/2016
ASCO2016: Kite Pharma (KITE) Presents Ongoing Complete Responses At 9 Months In Phase I Of ZUMA-1 In Patients With Chemorefractory Non-Hodgkin Lymphoma 6/6/2016
ASCO2016: Kite Pharma (KITE)/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma 6/6/2016
ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016 6/6/2016
ASCO2016 : AbbVie (ABBV) Presents Encouraging Phase 1 Data For Investigational Medicine ABT-414 As Monotherapy In Patients With An Aggressive Brain Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
Corcept Therapeutics Inc. (CORT) Provides Update Of Progress In Cortisol Modulation Oncology Program 6/6/2016
Mirati Therapeutics  (MRTX) Provides Progress Update On Current Clinical Trials 6/6/2016
ASCO2016: Astellas (ALPMY) And Seattle Genetics (SGEN) Present ASG-15ME And ASG-22ME Phase I Clinical Data In Metastatic Urothelial Cancer At ASCO Annual Meeting 6/6/2016
ASCO2016: DelMar Pharma Presents Phase I/II GBM Clinical Trial Data And Outlines Future Clinical Development Plans At ASCO 2016 Annual Meeting 6/6/2016
John Theurer Cancer Center Release: International Clinical Trial Suggests Value Of Venetoclax Combination Therapy In Patients With B-Cell Non-Hodgkin Lymphoma 6/6/2016
Aytu BioScience Announces Study Initiation And First Patient Dosing In Prostate Cancer Clinical Study With Hybridyne Imaging Technologies For Prostascint In Combination with Hybridyne's ProxiScan Transrectal Camera 6/6/2016
ASCO2016: Immunocore Presents Positive Imcgp100 Phase I Data At The 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: Berg Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: AstraZeneca PLC (AZN)'s Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer 6/6/2016
ASCO2016: Juno (JUNO)’s Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates In Adults With B-Cell ALL 6/6/2016
ASCO2016: CytRx (CYTR) Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: Merck & Co. (MRK) Release: New Data For KEYTRUDA (Pembrolizumab) In Combination With Talimogene Laherparepvec, Dabrafenib Plus Trametinib, Or Low-Dose Ipilimumab In Advanced Melanoma Presented At 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: Bristol-Myers Squibb (BMY) Promising Response Rates With Opdivo® (Nivolumab) Observed In Advanced Form Of Bladder Cancer From Phase I/II Study Checkmate -032 6/6/2016
ASCO2016: Xcovery Presents Results Of Plasma Genotyping Of Patients In The Exalt2 Study At The ASCO Annual Meeting 2016 6/6/2016
IgASCO2016: Ignyta (RXDX) Announces Interim Data From Phase 1 Clinical Trial Of Investigational Precision Medicine RXDX-105 At ASCO 2016 6/6/2016
ASCO2016: Pfizer (PFE) Presents Data From Phase Ib Trial Investigating Utomilumab (A 4-1BB Agonist) In Combination With A Checkpoint Inhibitor 6/6/2016
ASCO2016: Juno (JUNO) Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes And Tolerability 6/6/2016
ASCO2016: Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) And Yervoy (Ipilimumab) Combination Regimen Shows Clinically Meaningful Responses In First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase Ib Study Checkmate -012 6/6/2016
ASCO2016: Ariad (ARIA) Presents Long-Term Phase I/II Trial Follow Up On Investigational Drug Brigatinib With Median Time On Treatment Of 17 Months In ALK+ NSCLC Patients 6/6/2016
ASCO2016: VAXIMM Presents Data From Phase I Trial In Pancreatic Cancer With Oral T-Cell Immunotherapy VXM01 At ASCO 2016 Annual Meeting 6/6/2016
ASCO2016: AstraZeneca PLC (AZN) Release: Tagrisso (Osimertinib) Shows Clinical Activity In Patients With Leptomeningeal Disease From Lung Cancer 6/6/2016
ASCO2016: Mirna Announces Clinical Data On Its Lead Microrna Therapeutic Presented At ASCO 6/6/2016
ASCO2016: Peloton Therapeutics Presents Clinical Data On First-In-Class Oral HIF-2a Inhibitor In Patients With Advanced Kidney Cancer At 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: AstraZeneca PLC (AZN) Release: Tagrisso (Osimertinib) Shows Clinical Activity In Patients With Leptomeningeal Disease From Lung Cancer 6/6/2016
ASCO2016: Ariad (ARIA) Presents Data From Mutational Profiling In Crizotinib-Resistant Patients Treated With Investigational Medicine Brigatinib Showing Similar Response Rates In Patients With And Without Secondary ALK Mutations 6/6/2016
ASCO2016: Leap Therapeutics Presents Data From Phase I Single Dose Safety Study Of Anti-GITR Immunotherapy TRX518 In Patients With Advanced Relapsed Or Refractory Solid Tumors At American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting 6/6/2016
ASCO2016: MorphoSys AG Presents Updated Clinical Data For MOR202 In Multiple Myeloma And For MOR208 In Non-Hodgkin's Lymphoma At ASCO 2016 6/6/2016
ASCO2016: Aprea Announces Efficacy And Safety Data In High-Grade Serous Ovarian Cancer Patients Treated With Investigational APR-246 Presented At 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: Oncothyreon (ONTY) Presents Phase Ib Results Of ONT-380 In Combination With T-DM1 In HER2+ Metastatic Breast Cancer At ASCO 6/6/2016
ASCO2016: VBL Therapeutics (VBLX) VB-111 Clinical Data Presented At ASCO Demonstrate Significant Increase In Overall Survival In Platinum-Resistant Ovarian Cancer 6/6/2016
ASCO2016: NewLink Genetics (NLNK) Presents Clinical Data For IDO Pathway Inhibitor Indoximod Combinations At ASCO Annual Meeting 6/6/2016
ASCO2016: Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO 6/6/2016
Seattle Children's T-Cell Immunotherapy Clinical Trial For Children With Relapsed Leukemia Shows 93% Complete Remission Rate 6/3/2016
Dr. Hugh Rosen Joins Regulus (RGLS) Board Of Directors 6/3/2016
Novavax (NVAX) Announces New Seasonal Combination Respiratory Vaccine Program 6/3/2016
Arrien Pharmaceuticals LLC Initiated Phase I Clinical Trials Of ARN-6039 As A New Agent For Treatment Of Multiple Sclerosis (MS) 6/3/2016
Alnylam (ALNY) To Webcast Conference Call Discussing ALN-CC5 Phase I/II Data 6/3/2016
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City 6/3/2016
Why Cancer Patients And Doctors Should Rethink The Value Of Phase I Trials 6/3/2016
Polaris Group Release: ADI-PEG 20 Plus Gemcitabine And Nab-Paclitaxel Shows Robust Anti-Tumor Activity In Advanced Pancreatic Cancer 6/3/2016
ASCO2016: Cortice Biosciences Announces Presentation Of Results From A Phase I/II Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma At The Annual Meeting Of The ASCO 6/3/2016
Vectura (VEC.L) Reports Successful Completion Of VR942 Phase I Clinical Study 6/3/2016
FDA Grants Orphan Drug Designation To Debiopharms IAP Inhibitor Debio 1143 In The Treatment Of Ovarian Cancer 6/2/2016
Isofol Medical AB Has Successfully Advanced To The Next Dose Level Of Modufolin In A Phase I/II Clinical Trial In Colorectal Cancer 6/2/2016
Global Blood Therapeutics (GBT) To Host Investor Event On Friday, June 10 To Review GBT440 Data In Sickle Cell Disease Being Presented At The European Hematology Association's 21st Congress 6/2/2016
Enanta Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences 6/2/2016
MiNA Announces Initiation Of Phase I Clinical Study Of MTL-CEBPA In Patients With Liver Cancer 6/2/2016
FDA Grants Orphan Drug Designation For Retrotope’s RT001 In The Treatment Of Friedreich’s Ataxia 6/1/2016
Resolution Bioscience's ctDx Blood-Based NGS Platform Used For Plasma Genotyping And Longitudinal Monitoring Of ALK Fusion Positive Patients In Clinical Trial 6/1/2016
Viamet Receives Fast Track Designation From The FDA For VT-1129 For The Treatment Of Cryptococcal Meningitis 6/1/2016